1. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Issue 10 (22nd July 2014) Authors: Yale, J.‐F.; Bakris, G.; Cariou, B.; Nieto, J.; David‐Neto, E.; Yue, D.; Wajs, E.; Figueroa, K.; Jiang, J.; Law, G.; Usiskin, K.; Meininger, G.; on behalf of the DIA3004 Study Group Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 10(2014:Oct.) Page Start: 1016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗